P2Y12 Inhibitor Use During Aspirin Therapy for Prevention of ASCVD

P2Y12 inhibitor therapy in patients receiving aspirin therapy for ASCVD prevention does not affect the effectiveness of the aspirin therapy.

Related Keywords

United States ,American , ,Journal Of The American Heart Association ,American Heart ,Aspirin Dosing ,Patient Centric Trial Assessing Benefits ,Long Term Effectiveness ,